Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [Rapid Communication]

Conclusion
THP in patients with metastatic HER2-positive breast cancer is unlikely to be cost effective in the United States.

Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Durkee, Qian, Pollom, King, Dudley, Shaffer, Chang, Gibbs, Goldhaber-Fiebert, Horst Tags: Chemotherapy, Cost Effectiveness, Outcomes Research, Cost of Cancer Care, Rapid Communications Source Type: research